- Home
- NEWP vs FHTX Comparison
NEWP vs FHTX Comparison
Compare NEWP & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEWP
- FHTX
- Stock Information
- Founded
- NEWP 1972
- FHTX 2015
- Country
- NEWP Canada
- FHTX United States
- Employees
- NEWP N/A
- FHTX N/A
- Industry
- NEWP
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- NEWP
- FHTX Health Care
- Exchange
- NEWP Nasdaq
- FHTX Nasdaq
- Market Cap
- NEWP 259.4M
- FHTX 278.1M
- IPO Year
- NEWP N/A
- FHTX 2020
- Fundamental
- Price
- NEWP $1.70
- FHTX $5.56
- Analyst Decision
- NEWP
- FHTX Strong Buy
- Analyst Count
- NEWP 0
- FHTX 6
- Target Price
- NEWP N/A
- FHTX $11.33
- AVG Volume (30 Days)
- NEWP 174.3K
- FHTX 106.4K
- Earning Date
- NEWP 09-23-2025
- FHTX 08-05-2025
- Dividend Yield
- NEWP N/A
- FHTX N/A
- EPS Growth
- NEWP N/A
- FHTX N/A
- EPS
- NEWP N/A
- FHTX N/A
- Revenue
- NEWP N/A
- FHTX $24,173,000.00
- Revenue This Year
- NEWP N/A
- FHTX $33.60
- Revenue Next Year
- NEWP N/A
- FHTX $5.87
- P/E Ratio
- NEWP N/A
- FHTX N/A
- Revenue Growth
- NEWP N/A
- FHTX N/A
- 52 Week Low
- NEWP $0.93
- FHTX $2.95
- 52 Week High
- NEWP $2.05
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- NEWP 57.23
- FHTX 55.83
- Support Level
- NEWP $1.55
- FHTX $4.75
- Resistance Level
- NEWP $1.75
- FHTX $5.30
- Average True Range (ATR)
- NEWP 0.09
- FHTX 0.35
- MACD
- NEWP 0.00
- FHTX 0.03
- Stochastic Oscillator
- NEWP 85.71
- FHTX 90.04
About NEWP New Pacific Metals Corp.
New Pacific Metals Corp is a Canadian Mining Issuer, in the business of exploring and developing precious metal properties in Bolivia. The company's projects which are also its reportable segments include Silver Sand; Carangas and Silverstrike.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.